These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 20941938)

  • 1. [Proposal for biologic drugs therapy in rheumatoid arthritis].
    Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S; Kaliterna DM; Hanih M; Novak S
    Reumatizam; 2010; 57(1):29-35. PubMed ID: 20941938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis].
    Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S
    Reumatizam; 2008; 55(1):22-5. PubMed ID: 19024266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis].
    Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S
    Reumatizam; 2007; 54(1):16-9. PubMed ID: 18450272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
    Gibbons LJ; Hyrich KL
    BioDrugs; 2009; 23(2):111-24. PubMed ID: 19489652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part II. Tocilizumab, Abatacept, Rituximab--drugs characterised by a different mechanism of action than TNF-alpha inhibitors].
    Swierkot J; Madej M
    Pol Merkur Lekarski; 2011 Apr; 30(178):289-94. PubMed ID: 21595177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapies for treatment of rheumatoid arthritis.
    Smolen JS; Aletaha D; Koeller M; Weisman MH; Emery P
    Lancet; 2007 Dec; 370(9602):1861-74. PubMed ID: 17570481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatoid arthritis: Biological therapy other than anti-TNF.
    Rossi D; Modena V; Sciascia S; Roccatello D
    Int Immunopharmacol; 2015 Aug; 27(2):185-8. PubMed ID: 25840282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
    Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL
    J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis.
    Papagoras C; Voulgari PV; Drosos AA
    Autoimmun Rev; 2010 Jun; 9(8):574-82. PubMed ID: 20433955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biologic therapy of rheumatoid arthritis].
    Damjanov N; Vojinović J
    Srp Arh Celok Lek; 2009; 137(3-4):205-10. PubMed ID: 19459571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacotherapy of rheumatoid arthritis in the era of genetically engineered biological preparations].
    Nasonov EL
    Ter Arkh; 2007; 79(5):5-8. PubMed ID: 17672066
    [No Abstract]   [Full Text] [Related]  

  • 12. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New therapies for rheumatoid arthritis].
    Salgado E; Maneiro JR
    Med Clin (Barc); 2014 Nov; 143(10):461-6. PubMed ID: 24461738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Proposal of Croatian Society for Rheumatology for anti-TNF-alpha therapy in adult patients with spondyloarthritides].
    Babić-Naglić D; Laktasić N; Jajić Z; Anić B; Morović-Vergles J; Curković B;
    Reumatizam; 2007; 54(1):20-30. PubMed ID: 18450273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
    Belmonte Serrano MA; Pincus T
    Rheumatology (Oxford); 2010 Sep; 49(9):1795-6; author reply 1796-7. PubMed ID: 20484342
    [No Abstract]   [Full Text] [Related]  

  • 16. [Indications and efficacy of biologics in inflammatory arthritis].
    Combe B
    Bull Acad Natl Med; 2012 Oct; 196(7):1279-92; discussion 1293. PubMed ID: 23815014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic agents for rheumatoid arthritis: 2008 and beyond.
    Sweiss NJ; Hushaw LL
    J Infus Nurs; 2009; 32(1 Suppl):S4-17; quiz S19-24. PubMed ID: 19142153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy in rheumatoid arthritis.
    Köller MD
    Wien Med Wochenschr; 2006 Jan; 156(1-2):53-60. PubMed ID: 16465614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study.
    Rigby WF; Mease PJ; Olech E; Ashby M; Tole S
    J Rheumatol; 2013 May; 40(5):599-604. PubMed ID: 23547218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential use of biologic therapy in rheumatoid arthritis.
    Buch MH
    Curr Opin Rheumatol; 2010 May; 22(3):321-9. PubMed ID: 20190641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.